CA2901022C — Substituted pyridine compounds as inhibitors of histone demethylases
Assigned to Gilead Sciences Inc · Expires 2021-05-04 · 5y expired
What this patent protects
Compounds of the form In which Q is selected from -CH=NR12, W, -CH=2NHR13, CH=O and -CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathog…
USPTO Abstract
Compounds of the form In which Q is selected from -CH=NR12, W, -CH=2NHR13, CH=O and -CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.